Journal
FEMS MICROBIOLOGY LETTERS
Volume 362, Issue 24, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/femsle/fnv205
Keywords
endolysin; prophage; S. suis; lytic activity
Categories
Funding
- Key Project of Shanghai Municipal Agricultural Commission [2014-3-1]
- Basic Research Programs of Science and Technology Commission Foundation of Shanghai [12JC1404700]
- National Natural Science Foundation of China [31172381, 31372500, 31272580]
- Special Fund for Public Welfare Industry of Chinese Ministry of Agriculture [201303041]
Ask authors/readers for more resources
Streptococcus suis serotype 2 (S. suis 2) is a zoonotic pathogen that exhibits high-level resistance and multi-drug resistance to classic antibiotics and causes serious human casualties and heavy economic losses in the swine industry worldwide. Therefore, alternative therapies or novel antibacterial agents need to be developed to combat this pathogen. A novel endolysin derived from the S. suis temperate phage phi7917, termed Ly7917, was identified, which had broad lytic activity against S. suis type 1, 2, 7 and 9. Ly7917 consisted of an N-terminal cysteine, histidine-dependent amidohydrolases/peptidase catalytic domain and C-terminal SH3b cell wall binding domain. The endolysin maintained activity at high pH and its catalytic activity could be improved by addition of 10 mu M 1.5 mM Ca2+. In animal studies, 90% of BALB/c mice challenged with typical virulent strain HA9801 of S. suis 2 were protected by Ly7917 treatment. The bacterial load in the blood of HA9801-challenged mice was efficiently reduced almost 50% by Ly7917 while that of penicillin-G-treated mice kept almost unchanged. Our data suggest that Ly7917 may be an alternative therapeutic agent for infections caused by virulent S. suis strains.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available